Novel phosphoramidate derivatives of the anti-HIV nucleoside analogue d4T were designed to act as labile membrane-soluble prodrugs of the bio-active free nucleotide d4TMP. We herein reveal the very marked dependence of the antiviral activity of these phosphoramidates upon the stereochemistry of the amino acid attached to the phosphate centre; with a strong preference for the L-stereochemistry. These phosphate trlesters were shown to liberate amino acid derivatives of the nucleotide intracellularly. These novel analogues, typified by alaninyl d4T monophosphate, may act as intracellular sources of the free nucleotides. The alaninyl d4T adducts themselves exert an antiviral effect when administered extracellularly, but again with clear distinctions between the L-and D-series. This evidence indicates that extracellularly administered blocked triesters derived from L-amino acids can generate d4TMP lntracellularly, by a new pathway which is highly dependent on the amino acid stereochemistry.
In an attempt to improve on the therapeutic potential of current antiviral nucleoside analogues there have been reports on a variety of masked monophosphate derivatives, designed to act as membrane-soluble pro-drugs of the bio-active phosphate forms (Farrow et al., 1990; McGuigan et el., 1990a McGuigan et el., ,b,c, 1991 McGuigan et el., , 1992 Henin et al., 1991; Namane et al., 1992; Dessaux and Huynh-Dinh, Received22 February,1996; revised4 March,1996; accepted18 March,1996. *For correspondence. Tel. +44 012228745370; Fax+44 01222874180. 1993; Franchetti et al., 1994) . Although potent antiviral action has been noted in many of these cases, it has often been difficult to attribute clearly biological activity to intracellular nucleotide delivery rather than simply to extraand or intracellular nucleoside release.
The retention of activity in cells lacking thymidine kinase observed for certain phosphoramidate derivatives of AZT (McGuigan et al., 1993a) was taken as strong support for a mechanism of antiviral action independent of thymidine kinase. The simplest explanation is intracellular release of free nucleotides. Thus it was suggested that aryloxy phosphoramidates may represent true intracellUlar phosphate delivery forms (McGuigan et al., 1993a) . This technology has recently been applied to the promising anti-HIV nucleoside analogue 2',3'-didehydro-2',3 '-dideoxythymidined4T (3) . Again, phosphoramidates such as 1 appear to be effective prodrugs, with high potency and retention of activity in thymidine kinase-deficient cells (McGuigan et al., 1993b (McGuigan et al., , 1996a Balzarini et al., 1996) . Moreover, when applied to nucleoside analogues which are poorly effective, or inactive, such as 2',3'-dideoxyuridine, it was noted that the phosphoramidates are effective inhibitors of viral replication (McGuigan et al., 1994) . This process of activation of inactive nucleoside analogues has been termed 'kinase by-pass' (McGUigan et al., 1990a (McGUigan et al., , 1994 . In such cases, release of (inactive) nucleosides clearly cannot account for observed antiviral action, and nucleotide release becomes strongly implicated.
However, the exact mechanism by which aryloxy phosphoramidates exert their effect has remained unclear. Very recently, by use of the radio-labelled compound 1 it was noted that such phosphoramidates do indeed liberate free nucleotides inside intact cells (Balzarini et al., 1996) . Furthermore, it was observed that a novel metabolite (2) was formed in very high quantities (Balzarini et al., 1996; McGuigan et al., 1996a) .This paper probes the structureactivity relationships for the blocked triester 1 and the novel metabolite 2, with particular regard to the amino acid stereochemistry.
The synthetic strategy used for the preparation of the aryloxy phosphoramidates closely follows what has been previously reported for earlier analogues (McGuigan et al., 1993a) appropriate phosphorochloridate from phenyl phosphorodichloridate and an amino acid ester hydrochloride, followed by its reaction with the parent nucleoside analogue. In the first case, phenyl methyl-L-alaninyl phosphorochloridate (McGuigan et al., 1993a) was allowed to react with d4T (3) to give the phosphate triester 1 with natural L-stereochemistry at the amino acid (McGuigan et al., 1996a) . This was selectively hydrolysed using triethylamine and water to give the phosphate diester 2 (McGuigan et al., 1996a) . The isomers with altered D-stereochemistry at the amino acid were prepared with an entirely analogous procedure ( Fig. 1) . Thus, D-alanine methyl ester hydrochloride reacted with phenyl phosphorodichloridate to yield the necessary phosphorochloridate. This material was allowed to react with d4T to yield the triester 4, which was hydrolysed to the diester 5. Proton-, phosphorus-, and carbon-NMR and mass spectrometry data further confirmed the purity and structure of the new compounds 4 and 5. As with the previous L-compound 1, spectroscopic data on 4 fully confirmed the sample to be a 1:1 mixture of diastereoisomers about the phosphorus centre. However, all data are consistent with the complete retention of D-stereochemistry at the amino acid site in both 4 and 5. All samples were pure by HPLC, and entirely free of any contaminating d4T; this is particularly important given the high activity of d4T in the biological assays used.
The antiviral activities of compounds 1-5 were evaluated in two cell lines (human lymphocyte [wild-type] CEM/O and its thymidine kinase-deficient CEMITK-counterpart) against HIV-1 and HIV-2, with data recorded in Table 1 . Thus, the recently reported protected phosphoramidate 1 was found to be a very potent inhibitor of viral replication, and, in marked contrast to the parent nucleoside analogue 3, it retained full activity in thymidine kinase-deficient cells (Balzarini et al., 1996; McGuigan et al., 1996a) . This observation strongly suggests that phosphoramidates such as 1 owe little, if any, of their antiviral action to the release of the parent nucleoside analogue; otherwise some reduction in activity would have been observed in the TK-cells.
As noted in Table 1 , the novel D-series analogue 4 is ",,20-to 30-fold less active than the L-analogue 1. This reinforces our recent observation that the nature of the amino moiety is crucial for the eventual antiviral action, with simple amines being completely unable to substitute for amino acids (McGuigan et al., 1996b) . Interestingly, even though the D-triester 4 is relatively poorly active (EC so ",,211M), it does appear to retain full activity in thymidine kinase-deficient cells, again in marked contrast to the parent nucleoside analogue 3; indeed it is ",,1 O-fold more potent than d4T in these cells. Again, the triester appears to derive little, if any, of its antiviral action from nucleoside release (Table 1) . It is concluded that both L-(1) and D-(4) phosphoramidates derive the majority of their antiviral action via intracellular nucleotide release, rather than release of d4T (3), but that the L-compound achieves this with greater efficiency.
It has recently been noted that triester 1 releases a novel metabolite (2) in tissue culture, which may act as an intracellular source of free nucleotides (Balzarini et al., 1996; McGuigan et al., 1996a) . In order to clarify the role of metabolite 2 in the antiviral action of 1 and to probe whether this may be the origin of the above mentioned stereoselectivity, the corresponding analogue (5) was prepared with altered O-stereochemistry. Interestingly, 5 does have slight antiviral activity (Table  1) . Indeed, it is equally active with the corresponding triester 4. Moreover, although there is a slight (5-fold) reduction in activity for 5 in TK-cells, the compound is still (marginally) more active than d4T in these cells, indicating that d4T release alone would not account for the activity. A rather similar scenario is noted for the more active lisomer (2), with a 12-fold reduction in potency in TK-cells, but again a retention of significantly higher activity than d4T in such kinase-depleted cells. Thus, intracellular d4T monophosphate release is suggested as a significant mode of action of 2 and 5. It is interesting that the relative reduction in potency of the fully blocked phosphoramidates (1 and 4) vs. their corresponding hydrolysis products (2 and 5) is far higher in TK-cells; presumably since the latter materials can act via d4T release in the TK+ counterparts.
Whether the reduced antiviral action in the O-series relative to the parent l-series is due to reduced triphosphate generation directly from the protected O-series nucleotides, or altered intracellular pools of the putative intermediates (2 and 5), or reduced metabolism of 5 to d4TTP remains uncertain.
Thus, in conclusion, the importance of the amino acid stereochemistry for the anti-viral efficacy of phenoxy phosphoramidates derived from d4T is noted. Whether other SUbstituted amines are more effective than l-alanine is the subject of current intensive study in our laboratories. The direct activity of the novel partially hydrolysed phosphoramidate metabolites is also noted. In each case, the antiviral activity cannot be explained simply by nucleoside release, and intracellular delivery of the phosphoramidate metabolites as depot forms for the free monophosphates is suggested as a possible mechanism of action. The origins of the observed stereoselectivity in this mechanism are the subject of active investigation in our laboratories.
All experiments involving water-sensitive compounds were conducted under scrupulously dry conditions. Tetrahydrofuran was dried by heating under reflux over sodium and benzophenone, followed by distillation. N-methylimidazole was purified by distillation. Nucleoside (d4T) was dried by storage at elevated temperature in vacuo over P 205 . Proton, carbon and phosphorus Nuclear Magnetic Resonance CH, 13C, 31p NMR) spectra were recorded on a Bruker Avance OPX spectrometer (Bruker spectrospin, Germany/Switzerland) operating at 300 MHz, 75.5 MHz, and 121.5 MHz, respectively. All NMR spectra were recorded in COCI 3 or 0 20 at room temperature (20°C ± 3°C). 1Hand 13C chemical shifts are quoted in parts per million downfield from tetramethylsilane. J-values refer to coupling constants and signal splitting patterns are described as singlet (s), broad singlet (bs), doublet (d), triplet (t), quartet (q), multiplet (m) or combinations thereof. 31 P chemical shifts are quoted in parts per million relative to an external phosphoric acid standard. Many proton-and carbon-NMR signals of the phosphate triesters were split due to the presence of (phosphate) diastereoisomers in the samples. low resolution mass spectra were run on a VG Platform II Fisons instrument (Fisons, Altrincham, UK) (atmospheric pressure ionization, electrospray mass spectrometry) in either negative [ES-] or positive [ES+] ion mode. Chromatography refers to flash column chromatography and was carried out using Merck silica gel 60 (Sigma) (40-60 flM) as stationary phase. Thin layer chromatography was performed using Alugram Sil G/UV 2 54 aluminium backed silica gel plates. HPlC was conducted on an ACS quaternary system (ACS, Macclesfield, UK), using an 00S5 column and an eluant for phosphate triesters of water/acetonitrile, with 82% water 0-10 min, then a linear gradient to 20% water at 30 min, with a flow rate of 1 ml rnin" and detection by UV at 265 nm. For phosphate diesters an eluant of water/2-propanol was employed, with 99% 2-propanol 0-12 min, a linear gradient to 40% 2-propanol at 25 min, then 40% 2-propanol 25-40 min with a flow rate of 1 ml rnln" .
Phenyl methyl-O-alaninyl phosphorochloridate. A solution of triethylamine (279 ul., 203 mg, 2 mmol) in dry dichloromethane (3 ml) was added dropwise, over 1 h, to a mixture of phenyl phosphorodichloridate (422 mg, 2 mmol) and D-alanine methyl ester hydrochloride (307 mg, 2 mmol, 1 eq) in dry dichloromethane (10 mL) at -80°C. The reaction mixture was stirred for 14-16 hand allowed to reach room temperature over this time. The solvent was removed in vacuo and diethyl ether added to the residue (10 mL). Filtration of the precipitate and evaporation in vacuo afforded the title compound as a colourless oil which was used without further purification.
2',3'-didehydro-2', 3'-dideoxythymidine-S '-{phenyl methyl-D-alaninyljphosphate 4. In a flask provided with magnetic stirrer and nitrogen inlet d4T (3) (80 mg, 0.35 mmol) and N-methylimidazole (119~L, 1.5 mmol) were dissolved in THF (=3 mL). To this was added phenyl methyl-D-alaninyl phosphorochloridate (250 mg, 0.9 mmol), dissolved in THF (1 mL) dropwise with a syringe over 5 min, and the reaction mixture was left stirring for 14 h at room temperature. The mixture was dissolved in chloroform (= 50 mL) and washed with 1 M HCI (20 mL), saturated NaHC0 3 (20 mL), water (20 mL), dried, filtered and the solvent was evaporated.
The residue was chromatographed on silica using CHCI 3-MeOH 50: 1 as eluant. The title compound was obtained as a colourless residue. Yield: 94%. D H (CDCI 3 ) : 1.32, 1.35 (2xd, J = 7.1 Hz, 3H, Ala-Me), 1.77, 1.79 (2xs, 3H, 5-Me), 3.61 (s, 3H, Ala-C0 2Me), 3.70-4.00 (m, 2H, Ala-CH and Ala-NH), 4.22 (m, 2H, 5'CH 2 ) , 4.92 (s, 1H, 4'H), 5.80 (2xd, J = 5.7 Hz, 1H, 2'H), 6.26 (2xd, J = 5.7,1 H, 3'H), 6.96 (s, 1H, 1'H), 7. 6H, 6H and phenyl), 9.69, 9.73 (2xs, 1H, NH) ; Dc (CDCI 3 ) : 12.20, 12.28 (5-Me), 20.56, 20.64, 20.73, 20.79 (Ala-Me), 49.70, 49.95, 49.98 (Ala-C0 2Me), 52.44, 52.50 (Ala-CH), 66.08, 66.13, 66.94, 67.01 (5'C), 84.38, 84.41, 84.50 (4'C), 89.28, 89.58 (1'C), 111.11, 111.33 (5C), 119.94, 120.00, 120.05, 125.03 (phenyl), 127.07, 127.37 (2'C), 129.63 (phenyl), 132.94, 133.36 (3'C), 135.61,135.87 (6C), 150.12, 150.19150.26 (phenyl -ipso-) 2',3'-didehydro-2',3'-dideoxythymidine-S'-{Dalaninyljphosphate 5. In a flask provided with magnetic stirring and nitrogen inlet triester 4 (97.6 mg, 0.21 mmol) was dissolved in triethylamine-water 50:50 (10 mL, to make a 0.02 M solution). The mixture was vigorously stirred for 4 h and was then evaporated in vacuo at ambient temperature. The residue was chromatographed on silica with an eluant of isopropanol-water-concentrated aqueous ammonia (7:2:1). Appropriate fractions were pooled and evaporated in vacuo at ambient temperature. The title compound was obtained as a colourless residue. . CEM cells were infected with HIV-1 as previously described (Balzarini et al., 1993) . Briefly, 4x1 0 5 CEM cells mL-1 were infected with HIV-1 or HIV-2 at 100 CCID 50 (50% cell culture infective dose) mL of cell suspenslon". Then, 100~L of the infected cell suspension were transferred to microtitre plate wells and mixed with 100~L of the appropriate dilutions of the test compounds. After 4 days, giant cell formation was recorded microscopically in the HIV-infected cell cultures. The 50% effective concentration (EC 5 0 ) and 50% cytotoxic concentration (CC 5 0 ) were defined as the compound concentrations required to reduce by 50% the number of giant cells in the virus-infected cell cultures, and the number of viable cells in the mockinfected cell cultures, respectively.
